nach oben

Current Gastroenterology Reports

Erschienen in:

01.10.2014 | Large Intestine (B Cash, Section Editor)

Health Maintenance and Inflammatory Bowel Disease

verfasst von: Catherine S. Manolakis, Brooks D. Cash

Erschienen in: Current Gastroenterology Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory bowel disease (IBD) patients, specifically those with Crohn’s disease and ulcerative colitis, are at an increased risk of developing adverse events either related to disease course or therapeutic interventions. These risks can be mitigated by ensuring the patient is current on all aspects of their general health maintenance. This article is intended to serve as a guide regarding the health maintenance issues of the patient with IBD with recommendations for screening and surveillance intervals.

Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventative care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56:819–24.PubMedCrossRef

2.••

Di Palma JA, Farraye FA. Crohn’s disease: the first visit. Gasteroenterol Hepatol. 2011;7:163–9. An important review for the initiation and titration of immunomodulating medications.

Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135–9.PubMedCrossRef

Knox DL, Schachat AP, Mustonen E. Primary, secondary, coincidental ocular complications of Crohn’s disease. Ophthalmology. 1984;91:163–73.PubMedCrossRef

Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Opthalmol. 1982;14:256–360.

Manolakis C, Farraye FA, Di Palma JA. Crohn’s disease: the subsequent visit. Gastroenterol Hepatol. 2013;9:17–20.

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2, CD008794.PubMed

Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22.PubMedCrossRefPubMedCentral

9.••

Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–9. Important information regarding adverse effects of therapy; differs from what was previously reported. PubMedCrossRefPubMedCentral

10.

Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.PubMedCrossRefPubMedCentral

11.

Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:152–6.PubMedCrossRef

12.••

Targownik L, Bernstein C, Nugent Z, Leslie W. Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis. Clin Gastroenterol Hepatol. 2013;11:278–85. Interesting pathophysiologic review of osteoporosis in IBD. PubMedCrossRef

13.

Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995;10:250–6.PubMedCrossRef

14.

Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner. 1993;23:95–104.PubMedCrossRef

15.

Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417–22.CrossRef

16.

Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313–9.PubMedCrossRefPubMedCentral

17.

Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut. 2008;57:684–94.PubMedCrossRef

18.

Driscoll Jr RH, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83:1252–8.PubMed

19.

Krawitt EL, Beeken WL, Janney CD. Calcium absorption in Crohn’s disease. Gastroenterology. 1976;71:251–4.PubMed

20.

Kuwabara A, Tanaka K, Tsugawa N, et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009;20:935–42.PubMedCrossRef

21.

Silvennoinen J, Lamberg-Allardt C, Kakkainen M, et al. Dietar calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med. 1996;240:285–92.PubMedCrossRef

22.

Vagianos K, Bector S, Mcconnell J, et al. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31:311–9.PubMedCrossRef

23.

Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631–6.PubMedCrossRef

24.

Sing TT, Demets AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case–control study. Gastroenterology. 2009;136:451–8.CrossRef

25.

Sinclair J, Wasan S, Farraye FA. Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin N Am. 2012;41:325–37.CrossRef

26.

Cosnes J. What is the link between the use of tobacco and IBD? Inflamm Bowel Dis. 2008;14 suppl 2:S14–5.PubMedCrossRef

27.

Franchimont DP, Louis E, Croes F, Belaiche J. Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol. 1998;10:821–5.PubMedCrossRef

28.

Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity and comorbity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617–27.PubMedCrossRefPubMedCentral

29.

Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399–409.PubMedCrossRef

30.

Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 suppl 1:36–58.CrossRef

31.

Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003;327:1144–6.PubMedCrossRefPubMedCentral

32.

Graff L, Walker J, Bernstein C. It’s not just about the gut: managing depression and anxiety in inflammatory bowel disease. Pract Gastroenterol. 2011;62:11–25.

33.

Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.PubMedCrossRef

34.

Pai M, Zwerling A, Menziers D. Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177–84.PubMedCrossRefPubMedCentral

35.

Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619–33.PubMedCrossRef

36.

Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.PubMedCrossRef

37.

Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17:2536–40.PubMedCrossRef

38.

Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261–8.PubMedCrossRefPubMedCentral

39.

Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of innumosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–7.PubMedCrossRef

40.

Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60:456–62.

41.

Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.PubMedCrossRef

42.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2012;156:211–7.CrossRef

43.••

Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–9. Evolving information regarding live vaccines. PubMedPubMedCentral

44.

Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1–30.PubMed

45.

Kotton CN. Nailing down the shingles in IBD. Inflamm Bowel Dis. 2007;13:1178–9.PubMedCrossRef

46.

Singh A, Englund K. Q: who should receive the shingles vaccine? Cleve Clin J Med. 2009;76:48–8.

47.

Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States. Ann Intern Med. 2009;150:40–4.CrossRef

Titel: Health Maintenance and Inflammatory Bowel Disease
verfasst von: Catherine S. Manolakis
Brooks D. Cash
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 10/2014
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-014-0402-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Health Maintenance and Inflammatory Bowel Disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Demenzkranke durch Antipsychotika vielfach gefährdet

Drei Mythen bei der Antibiotikatherapie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

The Treatment of Cholangiocarcinoma: a Hepatologist’s Perspective

Narcotic Bowel Syndrome and Opioid-Induced Constipation

Impact of Inflammatory Bowel Disease on Disability

When Can Nutritional Therapy Impact Liver Disease?

Common Anorectal Conditions: Evaluation and Treatment

Tips and Tricks for Deep Jejunal Enteral Access: Modifying Techniques to Maximize Success

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Demenzkranke durch Antipsychotika vielfach gefährdet

Drei Mythen bei der Antibiotikatherapie

Update Innere Medizin